This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Peden, E. K. Articles by Lumsden, A. B. Search for Related Content PubMed Articles by Peden, E. K. Articles by Lumsden, A. B. Social Bookmarking                         What's this?

Fenoldopam Mesylate for the Prevention of Contrast Induced Nephropathy

Ruth Bush, MD

Alan B. Lumsden, MD

Baylor College of Medicine, Houston, Texas

A randomized controlled multicenter trail was conducted to determine the efficacy of fenoldopam mesylate in preventing contrast nephropathy after invasive cardiovascular procedures. The study measured serum creatinine levels at baseline and at 1, 24, 48 and 72 to 96 hours after drug administration. Patients (N = 315) with serum creatinine clearance of less than 60 mL/min were randomized to receive fenoldopam mesylate (n = 157) or placebo (n = 158). Twenty-eight centers participated in the study. Intravenous fenoldopam (0.05 gg/kg/min, titrated to 0.10 gg/kg/min) (or placebo) was started 1 hour prior to angiography and was continued for 12 hours. The endpoint of contrast-induced nephropathy occurred in 33.6% of the patients assigned to receive fenoldopam compared with 30.1% of patients who received the placebo. The difference in the 30-day death rate, need for dialysis, or rehospitalization between the two groups was not significant. The study concluded that fenoldopam mesylate does not prevent further renal deterioration after contrast administration in patients with chronic renal insufficiency.

Key Words: fenoldopam • contrast-induced nephropathy • renal failure

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 16, No. 4, 331-333 (2004)
DOI: 10.1177/153100350401600419


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?